Hope Medicine Inc. announces successful completion of its Phase Ib "An Open-Label Study on Safety and Efficacy of HMI-115 in Androgenetic Alopecia over 24 Weeks," advancing its research milestones.

Indapta Therapeutics Reveals Initial Treatment of Patients Using IDP-023, a Non-Self Derived NK Cell Treatment for Cancer Management.

PharmaLogic Holdings Corp. has struck a deal with clinical stage innovator ARTBIO for the production of AB001, an experimental prostate cancer treatment using lead-212.

FDA Sanctions Combination Use of Merck's KEYTRUDA (pembrolizumab) with Standard Chemoradiotherapy for Treating Stage III-IVA Cervical Cancer According to FIGO 2014 Criteria.

AskBio, part of the Bayer Group, commences a Phase II clinical study, GenePHIT, targeting the treatment of Congestive Heart Failure (CHF).

Elicio Therapeutics, Inc. announced the first participant treated in a Phase 2 trial of ELI-002 7P, an adjuvant monotherapy for KRAS-mutant pancreatic ductal adenocarcinoma.

Aclaris Therapeutics, working on immune-related treatments, shared initial Phase 2b results. They tested ATI-1777, a new topical JAK 1/3 inhibitor, on atopic dermatitis patients.

EyePoint Pharma reports initial participant receives treatment in early-stage VERONA study assessing EYP-1901 for diabetic eye swelling.

Ariceum Therapeutics has submitted an application for a Clinical Trial Authorization (CTA) in the UK to conduct initial trials of its novel Iodine-123 tagged PARP inhibitor, targeting recurrent glioblastoma patients.

Mirati Therapeutics, Inc. announced today that the European Commission has granted conditional approval for their medication, KRAZATI® (adagrasib).

Xeris Biopharma has announced a global licensing agreement with Amgen for a subcutaneous teprotumumab injection using its XeriJect® system for Thyroid Eye Disease.

The European Commission has approved STADA and Alvotech's biosimilar Uzpruvo® (AVT04), similar to Stelara® (ustekinumab), for marketing.